Rigel Pharmaceuticals Files 8-K on Financials

Ticker: RIGL · Form: 8-K · Filed: Aug 5, 2025 · CIK: 1034842

Rigel Pharmaceuticals Inc 8-K Filing Summary
FieldDetail
CompanyRigel Pharmaceuticals Inc (RIGL)
Form Type8-K
Filed DateAug 5, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, results-of-operations

Related Tickers: RGL

TL;DR

Rigel Pharma dropped an 8-K on financials, check it for the latest numbers.

AI Summary

Rigel Pharmaceuticals, Inc. filed an 8-K on August 5, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial status. No specific dollar amounts or significant events beyond routine reporting were detailed in the provided text.

Why It Matters

This filing provides investors with an official update on Rigel Pharmaceuticals' financial performance and condition, which can influence investment decisions.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for results of operations and financial condition, not indicating any immediate or unusual risks.

Key Players & Entities

  • Rigel Pharmaceuticals, Inc. (company) — Registrant
  • August 5, 2025 (date) — Date of earliest event reported
  • 611 Gateway Boulevard Suite 900 (address) — Principal executive offices
  • South San Francisco, CA 94080 (address) — Principal executive offices
  • (650) 624-1100 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Rigel Pharmaceuticals, Inc.'s results of operations and financial condition, including financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on August 5, 2025.

What is Rigel Pharmaceuticals, Inc.'s principal executive office address?

Rigel Pharmaceuticals, Inc.'s principal executive office is located at 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080.

What is the company's telephone number?

The company's telephone number, including area code, is (650) 624-1100.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on August 5, 2025 regarding RIGEL PHARMACEUTICALS INC (RIGL).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.